Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac Shares Down 12%

10/15/2021 | 01:07pm EST

By Josh Beckerman

CureVac NV shares were recently down 12%, to $39.99, three days after it said it would end development of its first-generation Covid-19 vaccine candidate.

According to a Reuters report citing German newspaper Rheinische Post, Bayer AG and CureVac terminated a vaccine production agreement.

On Thursday, CureVac shareholder Dievini Hopp Biotech Holding GmbH filed an amended Form 13-D with the U.S. Securities and Exchange Commission. The amendment reflects an internal reorganization related to share ownership and the transfer of some shares to CureVac in connection with an investment and shareholders' agreement.

The company said in June that the first-generation CVnCoV vaccine was 48% effective in providing protection against Covid-19 of any severity, a lower figure than the vaccines approved in the U.S. In August, CureVac reported favorable preclinical data for a second-generation vaccine candidate.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-15-21 1507ET

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 1.91% 45.37 Delayed Quote.-5.78%
CUREVAC N.V. -9.54% 43.62 Delayed Quote.-46.19%
All news about CUREVAC N.V.
11/30GSK names Pfizer scientist Dormitzer as vaccines R&D head
RE
11/19CureVac's Q3 Pretax Loss Widens, Revenue Rises
MT
11/19CureVac To Begin Trials Of COVID-19 Vaccine As Animal Testing Shows Strong Antibody Res..
MT
11/18CureVac to begin trials for next-generation COVID-19 shots within months
RE
11/18CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
11/18CUREVAC N : Announces Financial Results for the Third Quarter and First Nine Months of 202..
PU
11/18CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021..
EQ
11/18CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2C..
MT
11/18CUREVAC N : Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
PU
11/18CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, ..
EQ
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 140 M 158 M 158 M
Net income 2021 -401 M -454 M -454 M
Net cash 2021 1 249 M 1 413 M 1 413 M
P/E ratio 2021 -16,7x
Yield 2021 -
Capitalization 5 942 M 6 726 M 6 724 M
EV / Sales 2021 33,6x
EV / Sales 2022 1,86x
Nbr of Employees 505
Free-Float 45,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 38,54 €
Average target price 56,82 €
Spread / Average Target 47,4%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-46.19%6 726
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-41.09%23 827